|
Jul 2
|
RBC Raises Xenon Price Target, Cites Phase III Optimism for Epilepsy Drug
|
|
Jun 27
|
Xenon Joins the Russell 3000® and Russell 2000® Indexes
|
|
Jun 26
|
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
May 5
|
Xenon to Report Q1 2025 Financial Results on May 12, 2025
|
|
Apr 4
|
Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025
|
|
Feb 20
|
Xenon to Report Q4 and Full Year 2024 Financial Results on February 27, 2025
|